Quantcast
Last updated on April 24, 2014 at 6:40 EDT

Exagen Diagnostics Enters Into Exclusive Agreement With EndoChoice

February 16, 2010

ALBUQUERQUE, N.M., Feb. 16 /PRNewswire/ — Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced an exclusive sales and marketing agreement with EndoChoice, Inc. to promote its diagnostic services to gastroenterologists throughout the United States.

Under the agreement, EndoChoice’s experienced, gastroenterology-focused sales force will introduce Exagen’s proprietary gene expression tests for the diagnosis of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). Exagen developed these molecular tests through its discovery engine, Coperna®, which identified “gene activity signatures” associated with IBD and IBS.

Scott Glenn, Exagen’s CEO said, “We are excited about the opportunity of partnering with EndoChoice to accelerate the adoption of our technology by gastroenterologists. Our eXaIBD(TM) and eXaIBS(TM) tests have both high sensitivity and accuracy, helping to identify IBD and IBS from other diseases, avoiding an extensive series of exclusionary testing.”

“EndoChoice is focused on satisfying the unmet needs of GI professionals by delivering innovative, best-in-class products and services,” said Mark Gilreath, EndoChoice’s CEO. “We are pleased to offer Exagen’s proprietary eXaIBD(TM) and eXaIBS(TM) tests because they provide a superior diagnostic tool to assist gastroenterologists and improve patient care.”

About Exagen Diagnostics, Inc.

Exagen Diagnostics is the emerging leader in laboratory-discovered and developed genomic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna®, the company’s proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna’s targeted and precise discovery model has no conventional equivalent in the molecular diagnostics industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, please visit www.exagen.com.

About EndoChoice, Inc.

EndoChoice delivers innovative solutions to professionals in gastrointestinal endoscopy with its diverse portfolio of high-quality diagnostics, equipment, devices, supplies and services. The company strives to cleverly exceed its customers’ expectations through its nationwide sales force, exemplary customer care, superior products and easy online ordering. For more information, visit www.endochoice.com.

SOURCE Exagen Diagnostics, Inc.


Source: newswire